Literature DB >> 27075262

Liver: Osteopontin and HMGB1: novel regulators of HSC activation.

Lee A Borthwick1, Derek A Mann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27075262     DOI： 10.1038/nrgastro.2016.58

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

Review 2.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

3.  Osteopontin induces ductular reaction contributing to liver fibrosis.

Authors:  Xiaodong Wang; Aritz Lopategi; Xiaodong Ge; Yongke Lu; Naoto Kitamura; Raquel Urtasun; Tung-Ming Leung; Maria Isabel Fiel; Natalia Nieto
Journal:  Gut       Date:  2014-02-04       Impact factor: 23.059

Review 4.  OPN -Revisited.

Authors:  Vijayanirmala Subraman; Muthukumar Thiyagarajan; N Malathi; Sharada T Rajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 5.  Osteopontin in Immune-mediated Diseases.

Authors:  S R Rittling; R Singh
Journal:  J Dent Res       Date:  2015-09-04       Impact factor: 6.116

6.  Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice.

Authors:  J D Coombes; M Swiderska-Syn; L Dollé; D Reid; B Eksteen; L Claridge; M A Briones-Orta; S Shetty; Y H Oo; A Riva; S Chokshi; S Papa; Z Mi; P C Kuo; R Williams; A Canbay; D H Adams; A M Diehl; L A van Grunsven; S S Choi; W K Syn
Journal:  Gut       Date:  2014-06-05       Impact factor: 23.059

Review 7.  Cre-ativity in the liver: transgenic approaches to targeting hepatic nonparenchymal cells.

Authors:  Stephen N Greenhalgh; Kylie P Conroy; Neil C Henderson
Journal:  Hepatology       Date:  2015-04-13       Impact factor: 17.425

8.  Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection.

Authors:  Yasuhiro Matsue; Mikihiro Tsutsumi; Nobuhiko Hayashi; Takashi Saito; Mutsumi Tsuchishima; Nobuyuki Toshikuni; Tomiyasu Arisawa; Joseph George
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

Review 9.  Emerging role of HMGB1 in fibrotic diseases.

Authors:  Liu-Cheng Li; Jian Gao; Jun Li
Journal:  J Cell Mol Med       Date:  2014-10-06       Impact factor: 5.310

10.  Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.

Authors:  Elena Arriazu; Xiaodong Ge; Tung-Ming Leung; Fernando Magdaleno; Aritz Lopategi; Yongke Lu; Naoto Kitamura; Raquel Urtasun; Neil Theise; Daniel J Antoine; Natalia Nieto
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059
  10 in total
  4 in total

Review 1.  RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.

Authors:  Gowri Palanissami; Solomon F D Paul
Journal:  Horm Cancer       Date:  2018-07-09       Impact factor: 3.869

2.  Profibrogenic effect of high-mobility group box protein-1 in human dermal fibroblasts and its excess in keloid tissues.

Authors:  Won Jai Lee; Seung Yong Song; Hyun Roh; Hyo Min Ahn; Youjin Na; Jihee Kim; Ju Hee Lee; Chae Ok Yun
Journal:  Sci Rep       Date:  2018-05-30       Impact factor: 4.379

3.  Pathogenesis of NASH: The Impact of Multiple Pathways.

Authors:  Mazen Noureddin; Arun J Sanyal
Journal:  Curr Hepatol Rep       Date:  2018-10-31

Review 4.  Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells.

Authors:  Nancy Magee; An Zou; Yuxia Zhang
Journal:  Biomed Res Int       Date:  2016-10-16       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.